16 completed, 5 unknown, 2 active not recruiting, 1 not yet recruiting. 10 Phase 2, 9 Phase 1, 5 Phase 3, 4 Not applicable, 2 Phase 4.
Follow Excipients: new trials by email Literature Review of Excipients trials Research Report on Excipients
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ning Shen Dan Xiang Gao Fang for Heart-Kidney Disharmony Insomnia Ningshen Danxiang Donkey-hide Gelatin Medicated Paste, Ningshen Danxiang Agar Medicated Paste (agar as excipient) - Insomnia | Phase 2 | Not yet recruiting | Shanghai 7th People's Hospital | 60 | 2026-03-15 | 2026-04-01 |
| Effect of a Dietary Supplement on Lipid Pattern, Indexes of NAFLD and Systemic Inflammation in Healthy Subjects With Suboptimal LDL-C Levels Dietary supplement formulated with components of natural origin: artichoke, danshen, bergamot, folic acid, chromium and excipients., Placebo - Hypercholesterolemia, Inflammation | Not applicable | Unknown | University of Bologna | 90 | 2024-05-06 | 2024-05-08 |
| Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer Allogeneic mesenchymal stem cells (MSCs), Normal Saline - Diabetic Foot Ulcer | Phase 1 / Phase 2 | Unknown | Supergenics Life Science Sdn. Bhd. | 22 | 2024-05-01 | 2024-03-06 |
| Regulatory T Cells for Amyotrophic Lateral Sclerosis CK0803, Excipient - Amyotrophic Lateral Sclerosis | Phase 1 | Active not recruiting | Cellenkos, Inc. | 66 | 2023-04-03 | 2026-10-21 |
| Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome melatonin plus zinc, isomaltose and magnesium stearate - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Not applicable | Unknown | Laboratorios Viñas, S.A. | 106 | 2022-09-05 | 2022-07-12 |
| Effect of a Mixture of Allium Extracts on LDL Cholesterol Levels Volunteers With Elevated LDL Cholesterol Levels Garlic and onion concentrate, Control - Cardiovascular Health | Not applicable | Completed | DOMCA S.A. | 64 | 2021-02-01 | 2023-02-23 |
| Allium Extracts on the Incidence of Respiratory Infection Symptoms in Healthy Elderly Volunteers Garlic and onion concentrate, Control - Immunity | Not applicable | Completed | DOMCA S.A. | 66 | 2020-11-16 | 2022-05-23 |
| A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease bb1111 - Sickle Cell Disease | Phase 3 | Active not recruiting | Genetix Biotherapeutics Inc. | 35 | 2020-02-14 | 2024-12-10 |
| Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period Vildagliptin, Placebo - Disorder Related to Renal Transplantation, Diabetes | Phase 3 | Completed | Centre Hospitalier Universitaire de Besancon | 47 | 2018-10-26 | 2026-10-06 |
| Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline - Pompe Disease | Phase 1 | Completed | University of Florida | 2 | 2017-10-17 | 2022-04-05 |
| A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered Ticagrelor granule, Ticagrelor pediatric tablets, Ticagrelor pediatric tablets suspended in water - Sickle Cell Disease | Phase 1 | Completed | AstraZeneca | 44 | 2017-05-12 | 2017-08-02 |
| Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis Placebo, 5% VDA-1102, 10% VDA-1102 - Actinic Keratosis | Phase 2 | Completed | Vidac Pharma | 93 | 2016-07-15 | 2023-01-12 |
| Predicting, Understanding and Speeding Recovery After TKA Gabapentin, Placebo - Pain, Total Knee Replacement | Phase 4 | Terminated | Wake Forest University Health Sciences | 350 | 2016-06-02 | 2025-08-15 |
| CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED) Cyclosporine A, Placebo - Dry Eye Syndromes | Phase 2 | Completed | Novaliq GmbH | 207 | 2016-01-01 | 2019-11-06 |
| Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia Stemchymal®, Excipients - Cerebellar Ataxia | Phase 2 | Completed | Steminent Biotherapeutics Inc. | 56 | 2015-09-01 | 2022-10-27 |
| Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment Placebo, Pirfenidone - Alveolitis Extrinsic Allergic, Pulmonary Fibrosis | Phase 2 / Phase 3 | Unknown | Grupo Medifarma, S. A. de C. V. | 60 | 2015-07-01 | 2015-07-14 |
| Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water, Ticagrelor OD tablet (90 mg single dose) administered without water, Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube - Bioavailability, Healthy Subjects | Phase 1 | Completed | AstraZeneca | 100 | 2015-06-01 | 2016-09-29 |
| A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution Naloxegol 25 mg tablet, crushed, suspended in water, given orally, Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube, Naloxegol 25 mg (10 mL oral solution) - Bioavailability, Healthy Subjects | Phase 1 | Completed | AstraZeneca | 44 | 2015-05-01 | 2017-03-10 |
| A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease lovo-cel - Sickle Cell Disease | Phase 1 / Phase 2 | Completed | Genetix Biotherapeutics Inc. | 54 | 2015-02-02 | 2025-03-14 |
| Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery Simethicone, Oral Suspending Vehicle - Postoperative Ileus, Ileus | Phase 4 | Completed | McMaster University | 100 | 2014-10-01 | 2015-12-04 |
Showing 20 of 25. Sign in to see all of them.
Anemia, Sickle Cell (3) · Pain (2) · Sleep Initiation and Maintenance Disorders (2) · Abdominal Pain (1) · Acute Coronary Syndrome (1) · Alveolitis, Extrinsic Allergic (1) · Amyotrophic Lateral Sclerosis (1) · Anxiety Disorders (1) · Carcinoma, Squamous Cell (1) · Cerebellar Ataxia (1) · Cognitive Dysfunction (1) · Depression (1) · Diabetes Mellitus (1) · Diabetic Foot (1) · Dry Eye Syndromes (1)
AstraZeneca (3) · DOMCA S.A. (2) · Genetix Biotherapeutics Inc. (2) · University of Florida (2) · Cellenkos, Inc. (1) · Centre Hospitalier Universitaire de Besancon (1) · Grupo Medifarma, S. A. de C. V. (1) · Laboratorios Viñas, S.A. (1) · LigoCyte Pharmaceuticals, Inc. (1) · McMaster University (1) · Mesoblast, Inc. (1) · Novaliq GmbH (1) · Shanghai 7th People's Hospital (1) · Steminent Biotherapeutics Inc. (1) · Supergenics Life Science Sdn. Bhd. (1)
United States (10) · Spain (4) · Germany (3) · Canada (2) · Italy (2) · Mexico (2) · Australia (1) · China (1) · France (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Rainard Fuhr, Dr. med. (3) · Anjulika Chawla, MD, FAAP (2) · A. Ahsan Ejaz, MD (1) · Cagla Eskicioglu, MD, MSc (1) · Chaim M Brickman, MD (1) · Christopher James, PA (1) · Didier Ducloux, Pr. (1) · James C Eisenach, MD (1) · Jesus Z Villarreal-Perez, M.D. (1) · John J Treanor, MD (1) · Juan M Rodriguez, PhD (1) · Lilia Cardenas-Ibarra, M.D. (1) · Manuela Corti, P.T., PhD. (1)
PMID 20979455, PMID 26611780, PMID 27515308, PMID 30703441, PMID 31140114, PMID 31227028, PMID 31784348, PMID 32987448, PMID 33811823, PMID 34115136, PMID 34898139, PMID 34922648, PMID 36161320, PMID 42133908
P01GM113852 (1)